Novartis AG
NVS
$164.70
$2.031.25%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.39% | 8.47% | 12.32% | 11.87% | 15.14% |
| Total Other Revenue | 29.38% | 28.65% | 117.22% | 32.99% | 14.73% |
| Total Revenue | 2.23% | 9.00% | 15.26% | 12.38% | 15.13% |
| Cost of Revenue | 6.94% | 9.31% | 4.60% | 4.13% | 28.87% |
| Gross Profit | 0.70% | 8.91% | 18.74% | 15.20% | 11.30% |
| SG&A Expenses | -1.80% | 5.42% | 11.32% | 7.64% | 2.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 121.35% | -91.00% | -101.56% | -60.43% | -86.19% |
| Total Operating Expenses | 21.24% | 2.46% | 5.46% | 0.78% | 44.39% |
| Operating Income | -27.35% | 26.17% | 37.11% | 42.25% | -12.46% |
| Income Before Tax | -2.04% | 23.96% | 17.96% | 40.84% | 38.20% |
| Income Tax Expenses | 75.05% | 33.00% | -14.79% | 80.95% | 278.16% |
| Earnings from Continuing Operations | -14.75% | 23.39% | 23.97% | 34.26% | 6.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 350.00% | -150.00% | -- | -- | -- |
| Net Income | -14.51% | 23.17% | 24.49% | 34.15% | -66.77% |
| EBIT | -27.35% | 26.17% | 37.11% | 42.25% | -12.46% |
| EBITDA | -22.64% | 22.14% | 30.08% | 31.77% | -10.34% |
| EPS Basic | -11.20% | 28.68% | 29.92% | 39.33% | -65.72% |
| Normalized Basic EPS | -31.26% | 31.87% | 41.99% | 51.54% | -9.81% |
| EPS Diluted | -11.57% | 28.66% | 29.56% | 38.93% | -65.63% |
| Normalized Diluted EPS | -31.25% | 31.88% | 42.02% | 51.60% | -9.92% |
| Average Basic Shares Outstanding | -3.72% | -4.27% | -4.18% | -3.72% | -3.07% |
| Average Diluted Shares Outstanding | -3.74% | -4.29% | -4.20% | -3.75% | -2.95% |
| Dividend Per Share | 20.81% | -- | -- | -- | -1.44% |
| Payout Ratio | -- | -- | -0.17% | -0.24% | -- |